Durata Therapeutics has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) seeking approval for dalbavancin for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI).

The NDA submission follows the company’s clinical development programme, including positive results from two Phase III trials DISCOVER 1 and DISCOVER 2, as well as a previous Phase III study (VER-009).

Pharmaceutical firm Durata conducted both DISCOVER 1 and DISCOVER 2 trials under a special protocol assessment (SPA) with the FDA.

In November 2012, the FDA designated dalbavancin as a qualified infectious disease product, which provides Durata priority review by the agency, eligibility for fast-track status, and extension of statutory exclusivity periods for an additional five years after the product’s approval.

Durata said dalbavancin is a second generation, semi-synthetic lipoglycopeptide, which features lipophilic side-chains attached to glycopeptides.

According to the company, when compared with vancomycin, dalbavancin has a longer half-life resulting in a duration of antibacterial activity of five to seven days per dose.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company claims that if approved, dalbavancin would be the first drug for ABSSSI requiring once-weekly 30-minute intravenous doses, which may allow for the treatment of patients with ABSSSI in both inpatient and outpatient settings.

Durata Therapeutics chief executive officer Paul Edick said: "Dalbavancin is our first product candidate, and this milestone demonstrates our company’s commitment to improving patients’ lives by addressing the growing demand for therapeutics to treat acute illnesses and infectious diseases."

Image: Dalbavancin will be used for the treatment of patients with acute bacterial skin and skin structure infections. Photo: courtesy of